Identification of BCR::ABL1 Mutations by Digital PCR in CML

Official title

Digital PCR for Deep Sensitivity BCR::ABL1 Mutation Screening in CML

Overview

The goal of this study is to asses the ability of digital PCR (ddPCR) to detect actionable mutations in adult CML patients with failure of TKI therapy. The main objective of the study is it aims to answer is to assess whether ddPCR is at least as effective as NGS in detecting actionable (2GTKI-resistant) mutations. To accomplish this aim, samples of participants treated according to clinical practice, will be taken and analyzed for the presence of BCR::ABL1 KD mutations by ddPCR.

Detailed description

This is a multicenter biological study addressing the efficiency of ddPCR in detecting actionable mutations in patients with failure of TKI therapy. The study will involve 4 reference laboratories for BCR::ABL1 KD mutation testing Italian hematological centers enrolling patients and collecting samples for analysis.

Peripheral blood samples taken from patients treated according to clinical practice with resistance to imatinib or 2GTKI therapy according to the ELN recommendations will be shipped to one of the reference laboratories and analyzed by ddPCR using Bio-Rad ADS assays and reagents. Samples will be analyzed in batches of suitable size. ddPCR results will be compared with NGS results generated by reference laboratories belonging to LabNet CML network . In patients positive for mutations below 20% by ddPCR (low level mutations) peripheral blood sample(s) will be collected every 3 months at subsequent follow-up visits to monitor the kinetics of mutations in relation to therapy continuation or change.

No modification of TKI type or TKI dose will be performed on the basis of ddPCR results.

Interventions

• Other Peripheral blood withdrawal for BCR::ABL1 mutations testing
  Peripheral blood samples taken from patients treated according to clinical practice with resistance to imatinib or 2GTKI therapy according to the ELN recommendations will be shipped to one of the reference laboratories and analyzed by ddPCR using Bio-Rad ADS assays and reagents. Samples will be analyzed in batches of suitable size. ddPCR results will be compared with NGS results. In patients positive for mutations below 20% by ddPCR (low level mutations) peripheral blood sample(s) will be collec

Primary outcome measures

• Mutations detected by ddPCR [Time frame: At enrollment]

Eligibility criteria

Inclusion criteria

• molecularly confirmed diagnosis of BCR::ABL1+ CML;
• positivity for either e13a2 or e14a2 transcript;
• age ≥18 years;
• chronic phase;
• on therapy with imatinib or 2 GTKIs (dasatinib, nilotinib and bosutinib);
• candidate to TKI switch because of resistance according to the ELN recommendations OR with a confirmed warning response to 2GTKI therapy according to the ELN recommendations;
• Signed written informed consent according to ICH/EU/GCP and national local laws.

Exclusion criteria

• blastic phase;
• Previous allogeneic transplant or candidate to allogeneic transplant;
• on treatment with ponatinib or asciminib, investigational TKIs or non-TKI-therapy;
• switch performed or planned due to intolerance and not to resistance.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Screening

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07158294 · CML1725

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗